Cargando…
Lidocaine Ameliorates Diabetic Peripheral Neuropathy in Streptozotocin-Induced Diabetic Rats through Modulating the c-Jun Signaling Pathway
As one of the common complications of diabetes mellitus (DM), Diabetic Peripheral Neuropathy (DPN) threatens human lives seriously. Emerging evidences have confirmed the protective effects of lidocaine on DPN. However, the possible role and underlying mechanisms of lidocaine in DPN have not been cla...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402326/ https://www.ncbi.nlm.nih.gov/pubmed/36072636 http://dx.doi.org/10.1155/2022/1888153 |
_version_ | 1784773150059266048 |
---|---|
author | Luo, Jinyu Wu, Dedan Wu, Qianming Chen, Yan Gan, Yong He, Meng Sun, Wenyangming Ai, Yiqin Su, Qiuping Zou, Xiaohua Wang, Dashou |
author_facet | Luo, Jinyu Wu, Dedan Wu, Qianming Chen, Yan Gan, Yong He, Meng Sun, Wenyangming Ai, Yiqin Su, Qiuping Zou, Xiaohua Wang, Dashou |
author_sort | Luo, Jinyu |
collection | PubMed |
description | As one of the common complications of diabetes mellitus (DM), Diabetic Peripheral Neuropathy (DPN) threatens human lives seriously. Emerging evidences have confirmed the protective effects of lidocaine on DPN. However, the possible role and underlying mechanisms of lidocaine in DPN have not been clarified. In this study, the potential role of lidocaine in DPN is explored, and the possible mechanisms are investigated. The rat DPN model is constructed through administration of streptozotocin (STZ, 60 mg/kg). All rats are randomly divided into four groups, including the control group, DPN group, lidocaine (3.78 mg/time) group, and lidocaine combined with the SP600125 (15 mg/kg) group. Mechanical threshold, thermal latency, and blood glucose of rats before and after treatment are detected, and Nerve Conduction Velocity (NCV) is assessed. Moreover, qRT-PCR and western blot assays are carried out to determine the expressions of the c-Jun signaling pathway. The experimental results demonstrate that lidocaine remarkably downregulates the mRNA and protein expressions of the c-Jun signaling pathway in serum and DRGs induced with DPN. Besides, lidocaine combined with SP600125 can obtain better effects than lidocaine alone. It is clearly evident that lidocaine has a certain therapeutic effect on DPN. |
format | Online Article Text |
id | pubmed-9402326 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-94023262022-09-06 Lidocaine Ameliorates Diabetic Peripheral Neuropathy in Streptozotocin-Induced Diabetic Rats through Modulating the c-Jun Signaling Pathway Luo, Jinyu Wu, Dedan Wu, Qianming Chen, Yan Gan, Yong He, Meng Sun, Wenyangming Ai, Yiqin Su, Qiuping Zou, Xiaohua Wang, Dashou Contrast Media Mol Imaging Research Article As one of the common complications of diabetes mellitus (DM), Diabetic Peripheral Neuropathy (DPN) threatens human lives seriously. Emerging evidences have confirmed the protective effects of lidocaine on DPN. However, the possible role and underlying mechanisms of lidocaine in DPN have not been clarified. In this study, the potential role of lidocaine in DPN is explored, and the possible mechanisms are investigated. The rat DPN model is constructed through administration of streptozotocin (STZ, 60 mg/kg). All rats are randomly divided into four groups, including the control group, DPN group, lidocaine (3.78 mg/time) group, and lidocaine combined with the SP600125 (15 mg/kg) group. Mechanical threshold, thermal latency, and blood glucose of rats before and after treatment are detected, and Nerve Conduction Velocity (NCV) is assessed. Moreover, qRT-PCR and western blot assays are carried out to determine the expressions of the c-Jun signaling pathway. The experimental results demonstrate that lidocaine remarkably downregulates the mRNA and protein expressions of the c-Jun signaling pathway in serum and DRGs induced with DPN. Besides, lidocaine combined with SP600125 can obtain better effects than lidocaine alone. It is clearly evident that lidocaine has a certain therapeutic effect on DPN. Hindawi 2022-08-17 /pmc/articles/PMC9402326/ /pubmed/36072636 http://dx.doi.org/10.1155/2022/1888153 Text en Copyright © 2022 Jinyu Luo et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Luo, Jinyu Wu, Dedan Wu, Qianming Chen, Yan Gan, Yong He, Meng Sun, Wenyangming Ai, Yiqin Su, Qiuping Zou, Xiaohua Wang, Dashou Lidocaine Ameliorates Diabetic Peripheral Neuropathy in Streptozotocin-Induced Diabetic Rats through Modulating the c-Jun Signaling Pathway |
title | Lidocaine Ameliorates Diabetic Peripheral Neuropathy in Streptozotocin-Induced Diabetic Rats through Modulating the c-Jun Signaling Pathway |
title_full | Lidocaine Ameliorates Diabetic Peripheral Neuropathy in Streptozotocin-Induced Diabetic Rats through Modulating the c-Jun Signaling Pathway |
title_fullStr | Lidocaine Ameliorates Diabetic Peripheral Neuropathy in Streptozotocin-Induced Diabetic Rats through Modulating the c-Jun Signaling Pathway |
title_full_unstemmed | Lidocaine Ameliorates Diabetic Peripheral Neuropathy in Streptozotocin-Induced Diabetic Rats through Modulating the c-Jun Signaling Pathway |
title_short | Lidocaine Ameliorates Diabetic Peripheral Neuropathy in Streptozotocin-Induced Diabetic Rats through Modulating the c-Jun Signaling Pathway |
title_sort | lidocaine ameliorates diabetic peripheral neuropathy in streptozotocin-induced diabetic rats through modulating the c-jun signaling pathway |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402326/ https://www.ncbi.nlm.nih.gov/pubmed/36072636 http://dx.doi.org/10.1155/2022/1888153 |
work_keys_str_mv | AT luojinyu lidocaineamelioratesdiabeticperipheralneuropathyinstreptozotocininduceddiabeticratsthroughmodulatingthecjunsignalingpathway AT wudedan lidocaineamelioratesdiabeticperipheralneuropathyinstreptozotocininduceddiabeticratsthroughmodulatingthecjunsignalingpathway AT wuqianming lidocaineamelioratesdiabeticperipheralneuropathyinstreptozotocininduceddiabeticratsthroughmodulatingthecjunsignalingpathway AT chenyan lidocaineamelioratesdiabeticperipheralneuropathyinstreptozotocininduceddiabeticratsthroughmodulatingthecjunsignalingpathway AT ganyong lidocaineamelioratesdiabeticperipheralneuropathyinstreptozotocininduceddiabeticratsthroughmodulatingthecjunsignalingpathway AT hemeng lidocaineamelioratesdiabeticperipheralneuropathyinstreptozotocininduceddiabeticratsthroughmodulatingthecjunsignalingpathway AT sunwenyangming lidocaineamelioratesdiabeticperipheralneuropathyinstreptozotocininduceddiabeticratsthroughmodulatingthecjunsignalingpathway AT aiyiqin lidocaineamelioratesdiabeticperipheralneuropathyinstreptozotocininduceddiabeticratsthroughmodulatingthecjunsignalingpathway AT suqiuping lidocaineamelioratesdiabeticperipheralneuropathyinstreptozotocininduceddiabeticratsthroughmodulatingthecjunsignalingpathway AT zouxiaohua lidocaineamelioratesdiabeticperipheralneuropathyinstreptozotocininduceddiabeticratsthroughmodulatingthecjunsignalingpathway AT wangdashou lidocaineamelioratesdiabeticperipheralneuropathyinstreptozotocininduceddiabeticratsthroughmodulatingthecjunsignalingpathway |